278 related articles for article (PubMed ID: 24564526)
21. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
[TBL] [Abstract][Full Text] [Related]
22. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.
Clarke R; Liu MC; Bouker KB; Gu Z; Lee RY; Zhu Y; Skaar TC; Gomez B; O'Brien K; Wang Y; Hilakivi-Clarke LA
Oncogene; 2003 Oct; 22(47):7316-39. PubMed ID: 14576841
[TBL] [Abstract][Full Text] [Related]
23. Inferring coregulation of transcription factors and microRNAs in breast cancer.
Wu JH; Sun YJ; Hsieh PH; Shieh GS
Gene; 2013 Apr; 518(1):139-44. PubMed ID: 23246694
[TBL] [Abstract][Full Text] [Related]
24. Identification of Post-Transcriptional Modulators of Breast Cancer Transcription Factor Activity Using MINDy.
Campbell TM; Castro MA; Ponder BA; Meyer KB
PLoS One; 2016; 11(12):e0168770. PubMed ID: 27997592
[TBL] [Abstract][Full Text] [Related]
25. Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells.
Godinho M; Meijer D; Setyono-Han B; Dorssers LC; van Agthoven T
J Cell Physiol; 2011 Jul; 226(7):1741-9. PubMed ID: 21506106
[TBL] [Abstract][Full Text] [Related]
26. Ligand-Free Estrogen Receptor
Wang D; Lu R; Rempala G; Sadee W
Mol Pharmacol; 2019 Oct; 96(4):430-440. PubMed ID: 31399483
[TBL] [Abstract][Full Text] [Related]
27. MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy.
Yu X; Luo A; Liu Y; Wang S; Li Y; Shi W; Liu Z; Qu X
Mol Cancer; 2015 Dec; 14():208. PubMed ID: 26666173
[TBL] [Abstract][Full Text] [Related]
28. δEF1 down-regulates ER-α expression and confers tamoxifen resistance in breast cancer.
Guo S; Li Y; Tong Q; Gu F; Zhu T; Fu L; Yang S
PLoS One; 2012; 7(12):e52380. PubMed ID: 23285017
[TBL] [Abstract][Full Text] [Related]
29. Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state.
Kong SL; Li G; Loh SL; Sung WK; Liu ET
Mol Syst Biol; 2011 Aug; 7():526. PubMed ID: 21878914
[TBL] [Abstract][Full Text] [Related]
30. Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors.
Madak-Erdogan Z; Kieser KJ; Kim SH; Komm B; Katzenellenbogen JA; Katzenellenbogen BS
Mol Endocrinol; 2008 Sep; 22(9):2116-27. PubMed ID: 18617595
[TBL] [Abstract][Full Text] [Related]
31. Identification of upstream transcription factors (TFs) for expression signature genes in breast cancer.
Zang H; Li N; Pan Y; Hao J
Gynecol Endocrinol; 2017 Mar; 33(3):193-198. PubMed ID: 27809618
[TBL] [Abstract][Full Text] [Related]
32. Network motif-based identification of transcription factor-target gene relationships by integrating multi-source biological data.
Zhang Y; Xuan J; de los Reyes BG; Clarke R; Ressom HW
BMC Bioinformatics; 2008 Apr; 9():203. PubMed ID: 18426580
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
36. Insights into significant pathways and gene interaction networks underlying breast cancer cell line MCF-7 treated with 17β-estradiol (E2).
Huan J; Wang L; Xing L; Qin X; Feng L; Pan X; Zhu L
Gene; 2014 Jan; 533(1):346-55. PubMed ID: 23978611
[TBL] [Abstract][Full Text] [Related]
37. Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer.
Browne AL; Charmsaz S; Varešlija D; Fagan A; Cosgrove N; Cocchiglia S; Purcell S; Ward E; Bane F; Hudson L; Hill AD; Carroll JS; Redmond AM; Young LS
Oncogene; 2018 Apr; 37(15):2008-2021. PubMed ID: 29367763
[TBL] [Abstract][Full Text] [Related]
38. c-Jun/AP-1 overexpression reprograms ERα signaling related to tamoxifen response in ERα-positive breast cancer.
He H; Sinha I; Fan R; Haldosen LA; Yan F; Zhao C; Dahlman-Wright K
Oncogene; 2018 May; 37(19):2586-2600. PubMed ID: 29467493
[TBL] [Abstract][Full Text] [Related]
39. TF-centered downstream gene set enrichment analysis: Inference of causal regulators by integrating TF-DNA interactions and protein post-translational modifications information.
Liu Q; Tan Y; Huang T; Ding G; Tu Z; Liu L; Li Y; Dai H; Xie L
BMC Bioinformatics; 2010 Dec; 11 Suppl 11(Suppl 11):S5. PubMed ID: 21172055
[TBL] [Abstract][Full Text] [Related]
40. BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells.
Nehra R; Riggins RB; Shajahan AN; Zwart A; Crawford AC; Clarke R
FASEB J; 2010 Jun; 24(6):2040-55. PubMed ID: 20154269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
